Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 12/20 | 1.00 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19971879 | 1.00 | MBOAT4 (1.00) | MBOAT4ITGB3ITGA2BOPRK1KMT2A | |
| SCHEMBL18166105 | 1.00 | MBOAT4 (1.00) | MBOAT4ITGB3ITGA2BOPRK1KMT2A | |
| SCHEMBL19971862 | 0.93 | MBOAT4 (0.87) | MBOAT4ITGB3ITGA2BOPRK1 | |
| SCHEMBL16699286 | 0.93 | MBOAT4 (0.87) | MBOAT4ITGB3ITGA2BOPRK1 | |
| SCHEMBL16718758 | 0.93 | MBOAT4 (0.87) | MBOAT4ITGB3ITGA2BOPRK1 | |
| SCHEMBL19971834 | 0.91 | MBOAT4 (0.84) | MBOAT4ITGB3ITGA2BOPRK1 | |
| SCHEMBL19971835 | 0.91 | MBOAT4 (0.84) | MBOAT4ITGB3ITGA2BOPRK1 | |
| SCHEMBL16699191 | 0.90 | MBOAT4 (0.85) | MBOAT4ITGB3ITGA2BOPRK1KMT2A | |
| SCHEMBL18166109 | 0.90 | MBOAT4 (1.00) | MBOAT4ITGB3ITGA2BOPRK1 | |
| SCHEMBL18166103 | 0.90 | MBOAT4 (1.00) | MBOAT4ITGB3ITGA2BOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| WO-2016168225-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | MBOAT4, GIPR, PLAAT2 | MBOAT4 1/4885ITGB3 4128/4885ITGA2B 3681/4885 |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | MBOAT4, GIPR, PLAAT2 | MBOAT4 1/4885ITGB3 4128/4885ITGA2B 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.